Navigating Next-Generation Cellular Therapies

The 7investing Podcast · Feb 4, 2021 · 46m

The first chimeric antigen T-Cell Therapy (CAR-T) therapies were approved by the Federal Drug Administration (FDA) in 2017--these were heralded as “cures” for blood-borne cancers such as acute myeloid leukemia and aggressive non-Hodgkin’s Lymphoma.

Here, we have Simon Harnest, the Senior Vice President of Corporate Strategy and Finance of Cellectis (CLLS), unpacking where cell therapy is headed towards. Cellectis is the first company to envision an “off-the-shelf” approach to CAR-T therapy. Previous methods required long manufacturing times and complex methodologies to create a single…